Regnum Corp. CytoDyn Inc. and SevenScore Pharmaceuticals, LLC ("SevenScore"), announced the assignment of the Commercialization and License Agreement ("CLA") and a related Supply Agreement to commercialize leronlimab (PRO 140) in the U.S. for the treatment of HIV from SevenScore to Regnum. The CLA was signed between Vyera Pharmaceuticals, LLC ("Vyera") and CytoDyn on December 17, 2019 and assigned to SevenScore on October 29, 2020.

Under the terms of the CLA, Regnum has been granted an exclusive license to market and distribute leronlimab in the U.S. for the treatment of HIV and CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications. In exchange for such exclusive license, Regnum has agreed to pay regulatory and sales-based milestone payments, as well as a royalty of 50% on net sales.